AzTrials
AzTrials

Food AllergyNCT02504853

Natural History and Genetics of Food Allergy and Related Conditions

An observational study of Food Allergy and Loeys-Dietz Syndrome, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Background: About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: To learn more about the causes and effects of food allergy and related conditions. Read more about this study

Who is it for?
Ages 1 day to 99 yearsHealthy volunteers can take part
How many people
1,800 participants
Where
1 siteUnited States
Study dates
29 Jul 2015to 15 Jun 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: primary clinical

  • GENERAL INCLUSION CRITERIA:

All participants must meet the following criteria:

  1. Be 2 to 99 years-old at the time of enrollment for participants who will be seen at the NIH CC; be 0 (newborn) to 99 years-old at the time of enrollment for participants who will submit mail-in samples or participate in telehealth visits. Only viable neonates will be enrolled.
  2. Willing to allow storage of blood, buccal swabs, saliva, nasal swabs, stool samples, and other clinically appropriate tissue specimens for future use in medical research
  3. Required to have a primary care or other physician who will manage all health conditions related or unrelated to the study objectives

ADDITIONAL INCLUSION CRITERIA FOR AFFECTED PARTICIPANTS

In addition to the general criteria listed above, affected participants must meet 1 of the following criteria:

  1. Have a clinical history of an immediate hypersensitivity reaction to food(s) and be sensitized to food allergen(s) (as evidenced by positive SPT or allergen-specific IgE testing)
  2. Be sensitized (as evidenced by positive SPT or allergen-specific IgE testing) to food allergen(s) but have no overt clinical history of IgE-mediated symptoms when they eat that food(s)
  3. Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs)
  4. Have a diagnosis of eosinophilic esophagitis (EoE), or clinical suspicion for EoE as determined by the principal investigator (PI) or associate investigators (AIs)
  5. Have a history of atopic dermatitis based on self-report or physician assessment.

ADDITIONAL INCLUSION CRITERIA FOR UNAFFECTED RELATIVES:

In addition to the general criteria listed above, unaffected relatives must meet the following criteria:

  1. Be a relative of an affected participant
  2. Be unaffected by food allergy (as determined by clinical history and/or allergy testing) or be unaffected by the genetic condition under study

ADDITIONAL INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS

In addition to the general criteria listed above, healthy volunteers must meet the following criteria:

  1. Be unrelated to an affected participant
  2. Be unaffected by food allergy (as determined by clinical history and/or allergy testing) or be unaffected by the genetic condition under study

ADDITIONAL PROCEDURE- SPECIFIC INCLUSION CRITERIA:

The following additional inclusion criteria apply for participants undergoing leukapheresis:

  1. Age >= 18 years
  2. Stable hematologic parameters (definition: white blood cell count > 2,500/microL, hemoglobin > 10 g/dL, and platelet count > 75,000/microL)

GENERAL EXCLUSION CRITERIA:

Participants will be excluded for any of the following:

  • Presence of conditions that, in the judgment of the investigator or the referring physician, may put the participant at undue risk or make them unsuitable for participation in the study.
  • Inability to participate for the duration of the study.
  • The PI deems that participation in the study would not be expected to advance the study goals.

ADDITIONAL PROCEDURE- SPECIFIC EXCLUSION CRITERIA

Additional exclusion criteria apply for unaffected relatives and healthy volunteers who are undergoing endoscopy with biopsies for research purposes. Unaffected relatives and healthy volunteers will be excluded from participating in this procedure if they meet any of the following criteria:

  1. uncontrolled asthma or Grade 3 or higher by the American Society of Anesthesiologist s Physical Status Classification System (https://journals.lww.com/anesthesiologyopen/fulltext/2026/04000/american_society_of_anesthesiologists_statement_on.2.aspx)
  2. history of adverse reaction to conscious sedation or general anesthesia required for endoscopy
  3. hemoglobin < 11 g/dL
  4. platelet count < 100,000 microL
  5. PT INR >1.3 or PTT prolonged by > 3 seconds
  6. pregnant or breastfeeding
  7. viral screens positive for HIV or hepatitis B or C
  8. severe unstable myocardial ischemia or cardiomyopathy
  9. severe hypoxemia due to chronic pulmonary disease
  10. recent abdominal surgery
  11. anticoagulant therapy that cannot be interrupted
  12. history of reflux disease within the last 3 years or use of acid-suppression medication (including over-the-counter medications such as Tums, Rolaids, Zantac, Prilosec OTC, or Prevacid OTC) within the last 2 months
  13. chronic GI or immunologic disease
  14. clinically indicated EGD or colonoscopy within the past 12 months
  15. use of systemic or inhaled corticosteroids within the past 4 months
  16. have a history of EGID including EoE
  17. younger than 18 years of age

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ellen Zektser, R.N. contact

Not Listed

niaidfars@niaid.nih.gov

Pamela A Frischmeyer-Guerrerio, M.D. contact

(301) 402-9782

pamela.guerrerio@nih.gov

United States1 site, 1 recruiting
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892

    NIH Clinical Center Office of Patient Recruitment (OPR), 800-411-1222 ext. TTY dial 711, ccopr@nih.gov

    Recruiting

Other trials in United States

About this study

Background:

  • About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them.
Read more

Objective:

  • To learn more about the causes and effects of food allergy and related conditions.

Eligibility:

  • People ages 2 99 who have food allergy and/or a related genetic or other condition
  • Their relatives
  • Healthy relatives and volunteers

Design:

  • Participants will have at least 3 visits over 1 2 years, and then once a year for up to 12 years. Each may last a day or longer.
  • Participants will be screened with medical history, physical exam, and questionnaires.
  • Participants may have the following:
  • Blood tests
  • Allergy skin prick tests: Drops of allergens are placed on the back or arm. The skin is scratched under each drop.
  • Leukapheresis: blood is taken from a needle in one arm, passed through a machine, and returned through a needle in the other arm.
  • X-rays
  • Esophageal string test: One end of a string is taped to the cheek and the other end is packed into a capsule. When the capsule is swallowed, the string unwinds; it is left in for at least 1 hour.
  • EGD and colonoscopy: Biopsies are taken from the gastrointestinal system.
  • Tiny biopsies of skin
  • Photographs of the body
  • Collection of cells through:
  • Swab of nose, inside of cheek, or skin
  • Gentle skin scrape
  • Tape stripping: piece of tape is put on the skin and pulled off.
Read the detailed description

There are approximately 15 million Americans, including 6 million children, who have a potentially life-threatening food allergy. The prevalence of this disease has increased over the last three decades, in both the United States and other developed countries. There are no cures or effective prevention or treatment strategies for food allergy. Moreover, little is known about the factors that account for the rising prevalence and severity of these diseases in recent years. Both genetic and environmental factors likely contribute to the development of food allergy, but the complex interaction between these variables has frustrated efforts to elucidate pathogenesis and develop mechanism-targeted therapies. Children with food allergy are 2 to 4 times more likely to be diagnosed with asthma or other allergic conditions than children without food allergy, and food allergy may also be an important trigger for atopic dermatitis and eosinophilic esophagitis. The Laboratory of Allergic Diseases within the National Institute of Allergy and Infectious Diseases has a longstanding interest in the genetics and pathogenesis of allergic inflammatory disorders, and with the National Institutes of Health Clinical Center, it provides the ideal environment for the proposed translational studies. In this study, we will: (1) investigate the key genetic, cellular, immunologic, and biochemical pathways that lead to the development of food allergy, and (2) identify biomarkers that predict the clinical course and natural history of patients with food allergy.

Subjects eligible for enrollment in this study include children and adults with food allergy and patients with a known/suspected genetic or congenital disorder potentially associated with these phenotypes. Unaffected relatives (children and adults) of an enrolled subject and healthy volunteers (children and adults) will also be eligible for enrollment as controls. Most participants will be followed for 2 years, although participants with an identified genetic or congenital disorder and a subset of participants with food allergy may be followed until this study ends (up to 25 years).

Data obtained from analysis of blood, skin, saliva, stool, gastrointestinal biopsies, and other specimens will be used to explore the immunologic, biochemical, microbial, and genetic basis of food allergy. Results of research studies will be correlated with the scope and severity of their clinical phenotype, their response to treatment, and the natural history of their allergic disease(s).

Keywords
Eosinophilic Esophagitis, Loeys-Dietz Syndrome, Atopic Dermatitis, TGFbeta, Natural History
Medical subject headings
Food Hypersensitivity, Loeys-Dietz Syndrome, Dermatitis, Atopic, Eosinophilic Esophagitis, Camurati-Engelmann Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02504853
Study groupRoleWhat they receive
Affected GeneticHave a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs).
Affected Non-Syndromic FoodIndividuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
Allergic GI DiseaseIndividuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
Unaffected Relative / Healthy VolunteerUnaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Investigate the key genetic, cellular, immunologic, microbial, and biochemical pathways that lead to the development of food allergy

    Investigate the key genetic, cellular, immunologic, microbial, and biochemical pathways that lead to the development of food allergy

    Measured: 06/15/2025

  2. Identify biomarkers that predict the clinical course and natural history of patients with food allergy

    Identify biomarkers that predict the clinical course and natural history of patients with food allergy

    Measured: 06/15/2025

Secondary outcomes (3)
  1. The prevalence of eosinophilic GI disease in patients who might be considered to be at high risk for these conditions, including those patients with atopic dermatitis and/or multiple food sensitivities/allergies

    Measured: 06/15/2025

  2. In vitro testing of novel therapies for food allergy using cells and other biological specimens obtained from patients with food allergy

    Measured: 06/15/2025

  3. Identification of nutritional deficiencies and their effect on the growth and overall health of patients with food allergy and related conditions

    Measured: 06/15/2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2015 (estimated)
  2. Study start29 Jul 2015
  3. Primary completion15 Jun 2027 (estimated)
  4. Study completion15 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
1,800 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02504853
Sponsor's protocol ID
150162
Other IDs
15-I-0162
Status last verified
22 May 2026
First submitted
21 Jul 2015
Last updated
13 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All collected IPD.

Publications

  • Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C, Camargo CA Jr, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011 Jan;31(1):61-75. doi: 10.1016/j.nutres.2011.01.001. No abstract available.

    PubMed 21310308
  • Noval Rivas M, Burton OT, Wise P, Zhang YQ, Hobson SA, Garcia Lloret M, Chehoud C, Kuczynski J, DeSantis T, Warrington J, Hyde ER, Petrosino JF, Gerber GK, Bry L, Oettgen HC, Mazmanian SK, Chatila TA. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. J Allergy Clin Immunol. 2013 Jan;131(1):201-12. doi: 10.1016/j.jaci.2012.10.026. Epub 2012 Nov 30.

    PubMed 23201093
  • Frischmeyer-Guerrerio PA, Guerrerio AL, Oswald G, Chichester K, Myers L, Halushka MK, Oliva-Hemker M, Wood RA, Dietz HC. TGFbeta receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med. 2013 Jul 24;5(195):195ra94. doi: 10.1126/scitranslmed.3006448.

    PubMed 23884466
  • Kubala SA, Young FD, Callier V, Rasooly MM, Dempsey C, Mateja A, Brittain E, Frischmeyer-Guerrerio PA. Predictors of psychosocial burden in parents of children with food allergy. Ann Allergy Asthma Immunol. 2026 Aug;137(2):232-242.e8. doi: 10.1016/j.anai.2026.05.010. Epub 2026 May 20.

    PubMed 42155862

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in